Drugs / RD13-01
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04538599 | Sep 2020 → Feb 2021 | hematopoietic and lymphoid system neoplasm | He Huang | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04620655 | Nov 2020 → Nov 2021 | T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma | Min Xiang | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RD13-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04620655 ↗ |
| Modality | Cell therapy | “Universal CAR-T cells targeting CD7” NCT04538599 ↗ |
| Target | CD7 | “Universal CAR-T cells targeting CD7” NCT04538599 ↗ |